½ÃÀ庸°í¼­
»óǰÄÚµå
1637973

¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ±Ô¸ð ºÐ¼®, ±â¼úº°, Àü´Þ °æ·Îº°, »ý»ê ±â¼úº°, Àç·áº°, Áö¿ªº°, ¿¹Ãø(2022-2032³â)

Global Ophthalmic Drug Delivery Systems Market Size Study, By Technology, By Delivery Route, By Production Technology, By Material, and Regional Forecasts 2022-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 285 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ ¾à 147¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³âºÎÅÍ 2032³â¿¡ °ÉÃÄ CAGRÀº 6.6%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ ¼ºÀåÀº ¹é³»Àå, ³ì³»Àå, ³ëÈ­ Ȳ¹Ý º¯¼ºÁõ µî ´« ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¼¼°è 22¾ï ¸í ÀÌ»óÀÌ ½Ã°¢ °ü·Ã ¹®Á¦¿¡ ½Ã´Þ¸®°í ÀÖÀ¸¸ç, ´ëºÎºÐÀº Çõ½ÅÀûÀÎ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ÀÇÇÑ °íµµÀÇ Ä¡·á°¡ ÇÊ¿äÇÏ´Ù°í ÇÕ´Ï´Ù.

ÀÌ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ´Â °ÍÀº ¼­¹æÇü ÀÓÇöõÆ®, ÇÏÀ̵å·Î°Ö, ³ª³ëÀÔÀÚ¸¦ º£À̽º·Î ÇÑ µô¸®¹ö¸® ½Ã½ºÅÛÀ̶ó°í ÇÏ´Â ¼±Áø ±â¼úÀÇ Ã¤¿ëÀ̸ç, À̰Ϳ¡ ÀÇÇØ ¾à¹°ÀÇ »ýüÀÌ¿ë·ü°ú Ä¡·á ¼ºÀûÀÌ Çâ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â ³·Àº ü·ù¼º ¹× Èí¼ö Á¦ÇѰú °°Àº ÀüÅëÀûÀÎ Á¡¾ÈÁ¦ÀÇ ÇѰ踦 ÇØ°áÇϰí Ç¥ÀûÈ­µÈ ¾à¹° ¼­¹æ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ±æÀ» ¿­¾îÁÝ´Ï´Ù. ¶ÇÇÑ Ä¡·á¾÷°è¿¡¼­´Â ȯÀÚÀÇ ÄÄÇöóÀ̾𽺸¦ Áß½ÃÇÏ´Â °æÇâÀÌ °­ÇØÁö°í ÀÖÀ¸¸ç, ³·Àº ħ½À ¹× Àå½Ã°£ ÀÛ¿ëÇüÀÇ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ °³¹ßÀÌ ÃËÁøµÇ¾î Ä¡·á È¿À²ÀÌ ´ëÆø Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

°Ô´Ù°¡ Çõ½ÅÀûÀÎ Á¦Ç°¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú Á¦¾à ´ë±â¾÷ÀÇ ¿¬±¸ °³¹ß¿¡ ¸¹Àº ÅõÀÚ°¡ ÀÌ ºÐ¾ßÀÇ °­·ÂÇÑ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÇÏÀ̵å·Î°Ö°ú Æú¸®Ä«ÇÁ·Î¶ôÅæ°ú °°Àº »ýüÀûÇÕ¼º Àç·á´Â ¾à¹°Àü´Þ ¼º´É°ú ȯÀÚÀÇ ¾ÈÀü¼ºÀ» Çâ»ó½ÃŰ´Â ´É·ÂÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ ¹°ÁúÀº Áö¼ÓÀûÀÎ ¾à¹° ¹æÃâ ¸ÞÄ¿´ÏÁòÀ» º¸ÀåÇÏ°í ºó¹øÇÑ Àû¿ëÀÇ Çʿ伺À» ÁÙÀ̰í ȯÀÚÀÇ ÆíÀǼºÀ» Çâ»ó½Ãŵ´Ï´Ù.

Áö¿ªÀûÀ¸·Î´Â ºÏ¹Ì°¡ ½ÃÀåÀ» ¼±µµÇϰí ÀÖÀ¸¸ç, ±× ¹è°æ¿¡´Â È®¸³µÈ ÇコÄɾî ÀÎÇÁ¶ó, ¾öû³­ ¿¬±¸°³¹ß ÅõÀÚ, ´« °Ç°­¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¹Ý¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀº Àα¸ °í·ÉÈ­, ÀÇ·á ½Ã¼³ Á¢±Ù¼º Çâ»ó, Çõ½ÅÀûÀÎ Ä¡·á ¼Ö·ç¼ÇÀÇ Á߿伺 Áõ°¡¿¡ ÈûÀÔ¾î ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀÇ »ó¼¼ÇÑ ºÎ¹®¿Í ÇÏÀ§ ºÎ¹®Àº ´ÙÀ½°ú °°½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ÁÖ¿ä ¿ä¾à

  • ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
  • Áö¿ªº° °³¿ä
  • ºÎ¹®º° °³¿ä
    • ±â¼úº°
    • Àü´Þ °æ·Îº°
    • »ý»ê±â¼úº°
    • Àç·áº°
  • ÁÖ¿ä µ¿Çâ
  • °æ±â ÈÄÅðÀÇ ¿µÇâ
  • ¾Ö³Î¸®½ºÆ®ÀÇ ±Ç°í¿Í °á·Ð

Á¦2Àå ¼¼°è ¾È°ú ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå : Á¤ÀÇ¿Í ºÐ¼®ÀÇ ÀüÁ¦

  • ºÐ¼® ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ
  • ºÐ¼®ÀÇ ÀüÁ¦
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ »çÇ×
    • °ø±ÞÃø ºÐ¼®
      • °¡¿ë¼º
      • ÀÎÇÁ¶ó
      • ±ÔÁ¦ Ʋ
      • ½ÃÀå °æÀï
      • °æÁ¦¼º(¼ÒºñÀÚÀÇ ½ÃÁ¡)
    • ¼ö¿äÃø ºÐ¼®
      • ±ÔÁ¦ Ʋ
      • ±â¼úÁøº¸
      • ȯ°æ ¹è·Á
      • ¼ÒºñÀÚÀÇ Àǽİú ¼ö¿ë
  • ºÐ¼® ¹æ¹ý
  • ºÐ¼® ´ë»ó ±â°£
  • ȯÀ² º¯È¯À²

Á¦3Àå ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¾È°ú ÁúȯÀÇ ÀÌȯÀ² Áõ°¡
    • ¼­¹æ ±â¼úÀÇ Áøº¸
    • ȯÀÚ ÄÄÇöóÀ̾𽺠¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ½ÃÀåÀÇ °úÁ¦
    • ³ôÀº ¿¬±¸°³¹ßºñ
    • ±ÔÁ¦ÀÇ º¹À⼺
  • ½ÃÀå ±âȸ
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå È®´ë
    • °³º°È­ ¼Ö·ç¼ÇÀ» À§ÇÑ 3D ÇÁ¸°ÆÃ ä¿ë

Á¦4Àå ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷ °£ °æÀï °ü°è
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
    • ȯ°æÀû
    • ¹ýÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • Çõ½ÅÀÇ µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ ±Ç°í¿Í °á·Ð

Á¦5Àå ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ±â¼úº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå :¼öÀÍ µ¿Ç⠺м®, ±â¼úº°(2022³â¡¤2032³â)
    • ¾È¾à
    • ÄÜÅÃÆ®·»Áî
    • ÇÏÀ̵å·Î°Ö
    • ±âŸ

Á¦6Àå ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Àü´Þ °æ·Îº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå :¼öÀÍ µ¿Ç⠺м®, Àü´Þ °æ·Îº°(2022³â¡¤2032³â)
    • ¾È³»
    • À¯¸®Ã¼³»

Á¦7Àå ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : »ý»ê±â¼úº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå :¼öÀÍ µ¿Ç⠺м®, »ý»ê ±â¼úº°(2022³â¡¤2032³â)
    • ÀÏ·ºÆ®·Î ½ºÇÇ´×
    • 3D ÇÁ¸°ÆÃ
    • ó¹æ
    • ¾ÐÃâ ¼ºÇü
    • ¾ÐÃà ¼ºÇü

Á¦8Àå ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Àç·áº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¼öÀÍ µ¿Ç⠺м®, Àç·áº°(2022³â¡¤2032³â)
    • ÇÏÀ̵å·Î°Ö
    • Æú¸®Ä«ÇÁ·Î¶ôÅæ
    • PLGA
    • ±âŸ

Á¦9Àå ¼¼°èÀÇ ¾È°ú ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°(2022-2032³â)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦10Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
    • Ocular Therapeutix Inc.
    • Allergan plc.
    • Santen Pharmaceutical Co. Ltd.
  • ÁÖ¿ä ½ÃÀåÀÇ Àü·«
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦11Àå ºÐ¼® ÇÁ·Î¼¼½º

  • ºÐ¼® ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ¿¹Ãø
    • °ËÁõ
    • ÃâÆÇ
  • ºÐ¼®ÀÇ ¼Ó¼º
KTH 25.02.24

The global ophthalmic drug delivery systems market is valued at approximately USD 14.78 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% from 2024 to 2032. This growth is propelled by an increasing prevalence of eye disorders such as cataracts, glaucoma, and age-related macular degeneration. According to the World Health Organization, over 2.2 billion people globally are affected by vision-related problems, with many cases requiring advanced treatments facilitated by innovative drug delivery systems.

The market is driven by the adoption of advanced technologies like sustained-release implants, hydrogels, and nanoparticle-based delivery systems, which improve drug bioavailability and therapeutic outcomes. These advancements address limitations of traditional eye drops, such as poor retention and limited absorption, paving the way for targeted and sustained drug release solutions. The industry has also seen a growing focus on patient compliance, which has encouraged the development of minimally invasive and long-acting drug delivery systems, significantly enhancing treatment efficiency.

Furthermore, regulatory support for innovative products and heavy investments in R&D by pharmaceutical giants contribute to the sector's robust growth. Biocompatible materials like hydrogels and polycaprolactone are gaining prominence due to their ability to improve drug delivery performance and patient safety. These materials ensure sustained-release drug mechanisms, reducing the need for frequent applications and enhancing patient convenience.

Geographically, North America leads the market, driven by a well-established healthcare infrastructure, significant R&D investments, and rising awareness of eye health. Meanwhile, the Asia-Pacific region is projected to experience the fastest growth, fueled by an aging population, increased access to healthcare facilities, and a growing emphasis on innovative treatment solutions.

Major Market Players Included in This Report Are:

  • Ocular Therapeutix Inc.
  • Allergan plc.
  • Santen Pharmaceutical Co. Ltd.
  • Envisia Therapeutics
  • pSivida
  • Clearside Biomedical
  • Oculis Pharma
  • Valeant Pharmaceuticals
  • AptarGroup, Inc.
  • Novaliq GmbH
  • Orasis Pharmaceuticals
  • Viatris Inc.
  • Amneal Pharmaceuticals, Inc.
  • Eyenovia, Inc.
  • Bausch + Lomb

The Detailed Segments and Sub-Segments of the Market Are Explained Below:

By Technology:

  • Eye Drops
  • Contact Lenses
  • Punctal Plugs
  • Intravitreal Implants
  • Injectable Particulate Systems
  • Micro-Electromechanical Systems
  • Hydrogels
  • Others

By Delivery Route:

  • Intraocular
  • Intravitreal
  • Intracameral

By Production Technology:

  • Electrospinning
  • 3D Printing
  • Formulation
  • Extrusion
  • Compression Molding

By Material:

  • Hydrogels
  • Polycaprolactone
  • PLGA
  • Liposomes

By Region:

North America:

  • U.S.
  • Canada
  • Mexico

Europe:

  • UK
  • Germany
  • France
  • Italy

Asia-Pacific:

  • China
  • Japan
  • India
  • Australia

Latin America:

  • Brazil
  • Argentina

Middle East & Africa:

  • South Africa
  • Saudi Arabia

Years considered for the study are as follows:

  • Historical Year: 2022
  • Base Year: 2023
  • Forecast Period: 2024-2032

Key Takeaways:

  • Market estimates and forecasts for 10 years from 2022 to 2032.
  • Regional analysis for each segment.
  • Competitive landscape and key company profiles.
  • Analysis of major market drivers, challenges, and opportunities.
  • Detailed segmentation analysis with sub-segments and regional trends.

Table of Contents

Chapter 1. Global Ophthalmic Drug Delivery Systems Market Executive Summary

  • 1.1. Global Ophthalmic Drug Delivery Systems Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Technology
    • 1.3.2. By Delivery Route
    • 1.3.3. By Production Technology
    • 1.3.4. By Material
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Ophthalmic Drug Delivery Systems Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory Frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Ophthalmic Drug Delivery Systems Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Increasing prevalence of eye disorders
    • 3.1.2. Advancements in sustained-release technologies
    • 3.1.3. Growing demand for patient compliance solutions
  • 3.2. Market Challenges
    • 3.2.1. High R&D costs
    • 3.2.2. Regulatory complexities
  • 3.3. Market Opportunities
    • 3.3.1. Expanding markets in Asia-Pacific
    • 3.3.2. Adoption of 3D printing for personalized solutions

Chapter 4. Global Ophthalmic Drug Delivery Systems Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top Investment Opportunities
  • 4.4. Top Winning Strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Ophthalmic Drug Delivery Systems Market Size & Forecasts by Technology (2022-2032)

  • 5.1. Segment Dashboard
  • 5.2. Global Ophthalmic Drug Delivery Systems Market: Technology Revenue Trend Analysis (2022 & 2032)
    • 5.2.1. Eye Drops
    • 5.2.2. Contact Lenses
    • 5.2.3. Hydrogels
    • 5.2.4. Others

Chapter 6. Global Ophthalmic Drug Delivery Systems Market Size & Forecasts by Delivery Route (2022-2032)

  • 6.1. Segment Dashboard
  • 6.2. Global Ophthalmic Drug Delivery Systems Market: Delivery Route Revenue Trend Analysis (2022 & 2032)
    • 6.2.1. Intraocular
    • 6.2.2. Intravitreal

Chapter 7. Global Ophthalmic Drug Delivery Systems Market Size & Forecasts by Production Technology (2022-2032)

  • 7.1. Segment Dashboard
  • 7.2. Global Ophthalmic Drug Delivery Systems Market: Production Technology Revenue Trend Analysis (2022 & 2032)
    • 7.2.1. Electrospinning
    • 7.2.2. 3D Printing
    • 7.2.3. Formulation
    • 7.2.4. Extrusion
    • 7.2.5. Compression Molding

Chapter 8. Global Ophthalmic Drug Delivery Systems Market Size & Forecasts by Material (2022-2032)

  • 8.1. Segment Dashboard
  • 8.2. Global Ophthalmic Drug Delivery Systems Market: Material Revenue Trend Analysis (2022 & 2032)
    • 8.2.1. Hydrogels
    • 8.2.2. Polycaprolactone
    • 8.2.3. PLGA
    • 8.2.4. Others

Chapter 9. Global Ophthalmic Drug Delivery Systems Market Size & Forecasts by Region (2022-2032)

  • 9.1. North America Ophthalmic Drug Delivery Systems Market
    • 9.1.1. U.S. Ophthalmic Drug Delivery Systems Market
    • 9.1.2. Canada Ophthalmic Drug Delivery Systems Market
    • 9.1.3. Mexico Ophthalmic Drug Delivery Systems Market
  • 9.2. Europe Ophthalmic Drug Delivery Systems Market
    • 9.2.1. UK Ophthalmic Drug Delivery Systems Market
    • 9.2.2. Germany Ophthalmic Drug Delivery Systems Market
    • 9.2.3. France Ophthalmic Drug Delivery Systems Market
    • 9.2.4. Italy Ophthalmic Drug Delivery Systems Market
    • 9.2.5. Spain Ophthalmic Drug Delivery Systems Market
  • 9.3. Asia Pacific Ophthalmic Drug Delivery Systems Market
    • 9.3.1. China Ophthalmic Drug Delivery Systems Market
    • 9.3.2. Japan Ophthalmic Drug Delivery Systems Market
    • 9.3.3. India Ophthalmic Drug Delivery Systems Market
    • 9.3.4. Australia Ophthalmic Drug Delivery Systems Market
    • 9.3.5. South Korea Ophthalmic Drug Delivery Systems Market
  • 9.4. Latin America Ophthalmic Drug Delivery Systems Market
    • 9.4.1. Brazil Ophthalmic Drug Delivery Systems Market
    • 9.4.2. Argentina Ophthalmic Drug Delivery Systems Market
  • 9.5. Middle East & Africa Ophthalmic Drug Delivery Systems Market
    • 9.5.1. South Africa Ophthalmic Drug Delivery Systems Market
    • 9.5.2. Saudi Arabia Ophthalmic Drug Delivery Systems Market
    • 9.5.3. UAE Ophthalmic Drug Delivery Systems Market

Chapter 10. Competitive Intelligence

  • 10.1. Key Company SWOT Analysis
    • 10.1.1. Ocular Therapeutix Inc.
    • 10.1.2. Allergan plc.
    • 10.1.3. Santen Pharmaceutical Co. Ltd.
  • 10.2. Top Market Strategies
  • 10.3. Company Profiles

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦